Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Regulus Therapeutics Inc.
Fiscal year is January-December. All values USD millions. 2010 2011 2012 2013 5-year trend
Sales/Revenue - 8.6M 13.79M 12.7M 19.57M
Cost of Goods Sold (COGS) incl. D&A - - - - -
COGS excluding D&A - - - - -
Depreciation & Amortization Expense - 494,000 911,000 1.02M 1.36M
Depreciation - 455,000 816,000 900,000 1.26M
Amortization of Intangibles - 39,000 95,000 117,000 100,000
Gross Income - - - - -
2010 2011 2012 2013 5-year trend
SG&A Expense - 23.61M 20.02M 24.26M 36.01M
Research & Development - 20.18M 17.29M 20.34M 29.94M
Other SG&A - 3.43M 2.73M 3.92M 6.07M
Other Operating Expense - 0 0 0 0
Unusual Expense - 0 0 4.71M 1.15M
EBIT after Unusual Expense - 0 0 (4.71M) (1.15M)
Non Operating Income/Expense - 114,000 1,000 0 0
Non-Operating Interest Income - 157,000 128,000 110,000 292,000
Equity in Affiliates (Pretax) - 0 0 - 0
Interest Expense - 362,000 388,000 247,000 36,000
Gross Interest Expense - 362,000 388,000 247,000 36,000
Interest Capitalized - 0 0 0 0
Pretax Income - (15.59M) (7.4M) (17.42M) (18.69M)
Income Tax - (30,000) 206,000 (10,000) (23,000)
Income Tax - Current Domestic - 14,000 206,000 1,000 1,000
Income Tax - Current Foreign - 0 0 - -
Income Tax - Deferred Domestic - (44,000) 0 (11,000) (24,000)
Income Tax - Deferred Foreign - 0 0 - -
Income Tax Credits - 0 0 0 0
Equity in Affiliates - 0 0 0 0
Other After Tax Income (Expense) - 0 163,000 0 0
Consolidated Net Income - (15.56M) (7.44M) (17.41M) (18.67M)
Minority Interest Expense - 0 0 0 0
Net Income - (15.56M) (7.44M) (17.41M) (18.67M)
Extraordinaries & Discontinued Operations - 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets - 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations - 0 0 0 0
Net Income After Extraordinaries - (15.56M) (7.44M) (17.41M) (18.67M)
Preferred Dividends - 0 0 0 0
Net Income Available to Common - (15.56M) (7.44M) (17.41M) (18.67M)
EPS (Basic) - (0.46) (0.22) (2.12) (0.49)
Basic Shares Outstanding - 34.13M 34.13M 8.21M 38.48M
EPS (Diluted) - (0.46) (0.22) (2.12) (0.49)
Diluted Shares Outstanding - 34.13M 34.13M 8.21M 38.48M
EBITDA - (15M) (6.23M) (11.56M) (16.44M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.